IM Cannabis (IMCC) Competitors $2.83 +0.06 (+2.17%) (As of 02:50 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IMCC vs. EQ, CLDI, LSB, BTAI, CVKD, LSTA, XCUR, CMMB, TPST, and PULMShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Equillium (EQ), Calidi Biotherapeutics (CLDI), Lakeshore Biopharma (LSB), BioXcel Therapeutics (BTAI), Cadrenal Therapeutics (CVKD), Lisata Therapeutics (LSTA), Exicure (XCUR), Chemomab Therapeutics (CMMB), Tempest Therapeutics (TPST), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Equillium Calidi Biotherapeutics Lakeshore Biopharma BioXcel Therapeutics Cadrenal Therapeutics Lisata Therapeutics Exicure Chemomab Therapeutics Tempest Therapeutics Pulmatrix Equillium (NASDAQ:EQ) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends. Do institutionals & insiders believe in EQ or IMCC? 27.1% of Equillium shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 30.3% of Equillium shares are owned by company insiders. Comparatively, 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer EQ or IMCC? In the previous week, Equillium had 6 more articles in the media than IM Cannabis. MarketBeat recorded 6 mentions for Equillium and 0 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.71 beat Equillium's score of 0.38 indicating that IM Cannabis is being referred to more favorably in the news media. Company Overall Sentiment Equillium Neutral IM Cannabis Positive Which has preferable valuation and earnings, EQ or IMCC? IM Cannabis has higher revenue and earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$36.08M0.70-$13.34M-$0.14-5.08IM Cannabis$36.15M0.17-$7.04M-$3.41-0.83 Does the MarketBeat Community believe in EQ or IMCC? Equillium received 30 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 83.72% of users gave Equillium an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3683.72% Underperform Votes716.28%IM CannabisOutperform Votes642.86% Underperform Votes857.14% Is EQ or IMCC more profitable? Equillium has a net margin of -10.05% compared to IM Cannabis' net margin of -25.55%. Equillium's return on equity of -20.68% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Equillium-10.05% -20.68% -10.77% IM Cannabis -25.55%-129.86%-23.63% Which has more risk and volatility, EQ or IMCC? Equillium has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Do analysts rate EQ or IMCC? Equillium presently has a consensus price target of $5.00, indicating a potential upside of 603.23%. Given Equillium's stronger consensus rating and higher probable upside, research analysts plainly believe Equillium is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00IM Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryEquillium beats IM Cannabis on 14 of the 18 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.31M$1.29B$5.10B$8.84BDividend YieldN/AN/A5.04%4.07%P/E Ratio-0.8329.6595.6214.26Price / Sales0.178.981,217.1987.73Price / CashN/A11.6239.5936.27Price / Book2.052.066.946.36Net Income-$7.04M-$52.95M$118.89M$225.56M7 Day PerformanceN/A-2.69%-1.33%-0.10%1 Month Performance34.12%-2.06%-3.17%2.02%1 Year Performance12.30%6.03%32.49%27.87% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis0.7337 of 5 stars$2.83+2.2%N/A+12.6%$6.31M$36.15M-0.83340EQEquillium3.1992 of 5 stars$0.71-1.0%$5.00+603.2%+43.6%$25.19M$36.08M0.0040Analyst RevisionGap DownCLDICalidi Biotherapeutics2.5503 of 5 stars$2.24-2.2%$16.67+644.0%N/A$24.89M$50,000.000.0041Gap DownHigh Trading VolumeLSBLakeshore Biopharma0.2075 of 5 stars$2.67+1.9%N/AN/A$24.86M$80.82M0.00773BTAIBioXcel Therapeutics4.5363 of 5 stars$0.58-2.2%$5.00+769.4%-84.6%$24.59M$1.38M0.0090Gap DownCVKDCadrenal Therapeutics1.6952 of 5 stars$14.79+2.0%$18.00+21.7%N/A$24.55MN/A0.004LSTALisata Therapeutics3.3126 of 5 stars$2.82-3.8%$15.00+431.9%+33.6%$23.66MN/A-1.1730Analyst ForecastXCURExicure1.8055 of 5 stars$10.68-4.6%N/A+1,914.4%$23.18M$28.83M-4.9550News CoverageGap DownTrading HaltedCMMBChemomab Therapeutics2.8811 of 5 stars$1.57-4.2%$7.33+366.7%+228.0%$22.56MN/A0.0020TPSTTempest Therapeutics2.265 of 5 stars$0.89-0.8%$20.00+2,143.7%-76.2%$22.47MN/A-0.5920Analyst RevisionPULMPulmatrix0.2614 of 5 stars$6.15+9.4%N/A+210.5%$22.45M$7.30M-2.2820Analyst ForecastGap Up Related Companies and Tools Related Companies EQ Competitors CLDI Competitors LSB Competitors BTAI Competitors CVKD Competitors LSTA Competitors XCUR Competitors CMMB Competitors TPST Competitors PULM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMCC Stock Alerts